Prescient Therapeutics prepares for transformative year with new CEO and key FDA clearance
With new CEO James McDonnell in place and FDA clearance for its Investigational New Drug application, 2025...
With new CEO James McDonnell in place and FDA clearance for its Investigational New Drug application, 2025...
Proactive’s Tylah Tully gives a wrap of some of the strongest performers this week in...
Prescient Therapeutics Ltd has resolved the technical difficulties facing its OmniCAR program by creating a...
Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Prescient Therapeutics...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) is trading higher after receiving a green light from the...
Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), which is developing a pipeline of targeted,...
A strong and diversified pipeline has led Pitt Street Research to value Prescient Therapeutics Ltd (ASX:PTX,...
Clinical stage oncology company Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) had a cash and term deposit balance of $14.5...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), a clinical-stage oncology company developing personalised therapies for cancer, has...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) CEO and managing director Steven Yatomi-Clarke sits down with Jonathan...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.